How can we improve antibody-based cancer therapy?

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) are novel oncology therapeutics with demonstrated clinical efficacy.
• Current benefits are often limited, requiring combination therapies and yielding incremental improvements in progression-free survival (PFS) and overall survival (OS).
• The full potential of mAbs remains underexploited.

Purpose of the Study:

• To explore new approaches for enhancing the effectiveness of mAb therapies in oncology.
• To identify strategies for maximizing clinical benefit from monoclonal antibodies.

Main Methods:

• Review of current limitations and potential future directions for mAb therapy.
• Discussion of patient stratification based on tumor molecular characteristics.
• Consideration of strategies to improve mAb biodistribution and effector mechanisms like antibody-dependent cellular cytotoxicity (ADCC).

Main Results:

• Monoclonal antibodies (mAbs) show efficacy in oncology but benefits are often incremental.
• Combination therapies are frequently required, and only a fraction of patients respond.
• Potential exists for greater clinical benefit through targeted approaches.

Conclusions:

• Further exploitation of mAb potential requires novel strategies.
• Key areas for improvement include patient selection, enhanced biodistribution, and optimized immune effector functions (e.g., ADCC).
• These advancements aim to maximize therapeutic outcomes in cancer patients treated with mAbs.